Opportunity Information: Apply for RFA CA 25 006
This funding opportunity (RFA-CA-25-006) from the National Institutes of Health, specifically the National Cancer Institute (NCI), supports revision applications to active NCI-funded U01 projects. It is structured as a cooperative agreement (U01), meaning the funded work is expected to involve substantial scientific and/or programmatic involvement from NIH staff compared with a standard research grant. The central idea is straightforward: if a research team already has an ongoing NCI U01 project, they can request additional support to strengthen or speed up that parent project by adding in a novel technology that was developed with NCI Innovative Molecular Analysis Technologies (IMAT) program support. Clinical trials are optional under this NOFO, so projects may be either non-clinical or clinical in nature as long as they fit the revision scope.
The purpose of the revision is not to start a brand-new research direction unrelated to the parent award, but to expand the original research questions or accelerate progress toward the parent study goals by incorporating an IMAT-supported technical approach or device. In practice, that means proposing a well-justified integration of an emerging IMAT technology into the ongoing U01 research plan, with clear explanation of how the added technology enables stronger experimentation, faster or more informative data generation, better measurement capabilities, improved analytical performance, or otherwise increases the likelihood of timely scientific advances. A major emphasis is on independent validation, encouraging applicants to test and demonstrate that these new tools actually perform as expected in real research settings, and to help move the technologies closer to being broadly usable by the appropriate cancer research communities.
Programmatically, the NOFO sits within the NCI IMAT ecosystem and is designed to push interdisciplinary collaboration, especially collaborations that bridge technology development with real-world cancer research use cases. The expectation is that adding the IMAT-derived tool or method will not just be a peripheral add-on, but a meaningful enhancement that improves the rigor, reproducibility, suitability, or translational readiness of the ongoing study. This can include improved molecular analysis methods, devices, or other innovative measurement and analysis technologies that IMAT has supported, with the revision funds serving as an incentive to evaluate and deploy them in a way that demonstrates value and accelerates adoption.
From an administrative standpoint, the opportunity is categorized as discretionary funding and is associated with the Health and Education activity category. The CFDA number listed is 93.394. The application deadline is 2025-10-03. The award ceiling is $150,000, and NCI anticipates making about 3 awards under this announcement, indicating a relatively competitive, targeted effort focused on a small number of high-impact revisions.
Eligibility is broad and includes many types of domestic organizations, including state, county, and local governments; special district governments; independent school districts; public and state-controlled institutions of higher education; private institutions of higher education; federally recognized Native American tribal governments; tribal organizations (including those other than federally recognized tribal governments); public housing authorities/Indian housing authorities; nonprofits with or without 501(c)(3) status (outside of higher education); for-profit organizations (other than small businesses); and small businesses. The NOFO also highlights additional eligible applicant types such as Alaska Native and Native Hawaiian Serving Institutions, Asian American Native American Pacific Islander Serving Institutions (AANAPISIs), Hispanic-serving Institutions, Historically Black Colleges and Universities (HBCUs), Tribally Controlled Colleges and Universities (TCCUs), faith-based or community-based organizations, eligible federal agencies, regional organizations, U.S. territories or possessions, and even non-domestic (non-U.S.) entities (foreign organizations), reflecting an intent to support diverse institutional participation where it aligns with the parent U01 award structure and goals.
Overall, this NOFO is best understood as a focused supplement-like pathway for existing NCI U01 teams to bring an IMAT-backed innovation into their ongoing cancer research, generate credible validation data, and deliver a faster or more definitive trajectory toward the scientific objectives of the parent project, with NCI actively involved through the cooperative agreement mechanism.Apply for RFA CA 25 006
- The National Institutes of Health in the education, health sector is offering a public funding opportunity titled "Revision Applications for Incorporation of Novel NCI- Supported Technology to Accelerate Cancer Research (U01 Clinical Trial Optional)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.394.
- This funding opportunity was created on 2024-12-31.
- Applicants must submit their applications by 2025-10-03. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- Each selected applicant is eligible to receive up to $150,000.00 in funding.
- The number of recipients for this funding is limited to 3 candidate(s).
- Eligible applicants include: State governments, County governments, City or township governments, Special district governments, Independent school districts, Public and State controlled institutions of higher education, Native American tribal governments (Federally recognized), Public housing authorities/Indian housing authorities, Native American tribal organizations (other than Federally recognized tribal governments), Nonprofits having a 501 (c) (3) status with the IRS, other than institutions of higher education, Nonprofits that do not have a 501 (c) (3) status with the IRS, other than institutions of higher education, Private institutions of higher education, For-profit organizations other than small businesses, Small businesses, Others.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Frequently Asked Questions (FAQs)
What is the funding opportunity RFA-CA-25-006?
RFA-CA-25-006 is a National Institutes of Health (NIH) funding opportunity from the National Cancer Institute (NCI) that supports revision applications to active NCI-funded U01 projects. The goal is to provide additional support to strengthen or accelerate the existing (parent) U01 project by incorporating a novel technology that was developed with support from NCI's Innovative Molecular Analysis Technologies (IMAT) program.
What type of award is this?
This opportunity is a cooperative agreement (U01). A cooperative agreement means NIH/NCI staff are expected to have substantial scientific and/or programmatic involvement in the funded work compared with a standard research grant.
Who is this opportunity intended for?
It is intended for research teams that already have an active NCI-funded U01 project and want to submit a revision application to integrate an IMAT-supported technology into that ongoing research.
What is a "revision application" in the context of this announcement?
In this announcement, a revision application is a request for additional support to expand, strengthen, or speed up progress on an active parent NCI U01 award. The revision is meant to enhance the existing project rather than start an unrelated new research direction.
What is the main purpose of the revision funding?
The main purpose is to add a novel IMAT-supported technology (such as an innovative molecular analysis method, device, or other measurement/analysis technology) to the parent U01 project in a way that meaningfully improves the study. This could include enabling stronger experiments, generating data faster or with greater informativeness, improving measurement capabilities, improving analytical performance, or otherwise increasing the likelihood of timely scientific advances.
Does the proposed revision have to be related to the parent U01 project?
Yes. The revision is not intended to launch a brand-new research direction unrelated to the parent award. It should expand the original research questions or accelerate progress toward the parent study goals through integration of an IMAT-supported approach or device.
What kinds of technologies are expected to be added through this revision?
The revision is designed to support incorporation of emerging technologies that were developed with support from NCI's IMAT program. These can include improved molecular analysis methods, devices, or other innovative measurement and analysis technologies backed by IMAT support.
How significant must the IMAT technology integration be?
The expectation is that the IMAT-derived tool or method is not just a peripheral add-on. It should be a meaningful enhancement that improves rigor, reproducibility, suitability, or translational readiness of the ongoing study and helps accelerate progress toward the parent project objectives.
Is independent validation of the technology emphasized?
Yes. A major emphasis is on independent validation. Applicants are encouraged to test and demonstrate that the IMAT-supported tools perform as expected in real research settings and to generate credible validation data that help move the technology closer to broad usability by relevant cancer research communities.
Are clinical trials allowed under this NOFO?
Clinical trials are optional under this notice of funding opportunity (NOFO). Projects may be non-clinical or clinical in nature as long as they fit within the scope of a revision to the active parent U01 and align with the purpose of integrating an IMAT-supported technology.
How does this opportunity connect to the NCI IMAT program?
This NOFO sits within the NCI IMAT ecosystem and is designed to promote interdisciplinary collaboration, especially collaborations that connect technology development with real-world cancer research use cases. The revision funding serves as an incentive to evaluate and deploy IMAT-backed innovations in ongoing NCI U01 research.
What is meant by "substantial involvement" from NIH staff?
Because this is a cooperative agreement (U01), NIH/NCI staff are expected to have substantial scientific and/or programmatic involvement in the project compared with a standard research grant. This reflects a more active partnership model during the conduct of the funded work.
What is the maximum award amount (award ceiling)?
The award ceiling listed for this opportunity is $150,000.
How many awards does NCI expect to make?
NCI anticipates making about 3 awards under this announcement, indicating a targeted and competitive funding effort.
What is the application deadline?
The application deadline is 2025-10-03.
What is the CFDA number associated with this opportunity?
The CFDA number listed is 93.394.
What activity category is this opportunity associated with?
The opportunity is associated with the Health and Education activity category.
Is this considered discretionary funding?
Yes. From an administrative standpoint, the opportunity is categorized as discretionary funding.
What types of organizations are eligible to apply?
Eligibility is broad and includes many domestic organization types, including:
- State, county, and local governments
- Special district governments
- Independent school districts
- Public and state-controlled institutions of higher education
- Private institutions of higher education
- Federally recognized Native American tribal governments
- Tribal organizations (including those other than federally recognized tribal governments)
- Public housing authorities/Indian housing authorities
- Nonprofits with or without 501(c)(3) status (outside of higher education)
- For-profit organizations (other than small businesses)
- Small businesses
Are any additional institution types explicitly highlighted as eligible?
Yes. The NOFO highlights additional eligible applicant types, including Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISIs); Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Tribally Controlled Colleges and Universities (TCCUs); faith-based or community-based organizations; eligible federal agencies; regional organizations; U.S. territories or possessions; and non-domestic (non-U.S.) entities (foreign organizations).
Can foreign (non-U.S.) organizations apply?
Yes. The NOFO indicates that non-domestic (non-U.S.) entities (foreign organizations) are included among eligible applicant types, reflecting an intent to support diverse institutional participation where it aligns with the parent U01 award structure and goals.
Is this opportunity appropriate for teams without an active NCI U01 award?
Based on the description provided, the opportunity supports revision applications to active NCI-funded U01 projects. That implies it is intended for teams with an existing active NCI U01 parent award rather than new applicants proposing a stand-alone project.
What outcomes is NCI trying to achieve through these revisions?
NCI is aiming to speed progress and strengthen ongoing U01 cancer research by integrating IMAT-backed innovations, generating credible validation data, improving rigor and reproducibility, and moving promising technologies closer to broader adoption by the relevant cancer research communities.
Browse more opportunities from the same category: Education, Health
Next opportunity: Office of Elementary and Secondary Education (OESE): Office of Indian Education (OIE): Indian Education Discretionary Grants Program: Demonstration Grants for Indian Children and Youth Program, Assistance Listing Number (ALN) 84.299A
Previous opportunity: Disability and Rehabilitation Research Projects (DRRP) Program: Employment (Development)
Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for RFA CA 25 006
Applicants also applied for:
Applicants who have applied for this opportunity (RFA CA 25 006) also looked into and applied for these:
| Funding Opportunity |
|---|
| Academic-Industrial Partnerships for Translation of Technologies for Diagnosis and Treatment (R01 - Clinical Trial Optional) Apply for PAR 25 337 Funding Number: PAR 25 337 Agency: National Institutes of Health Category: Education, Health Funding Amount: $499,000 |
| Academic-Industrial Partnerships for Translation of Technologies for Diagnosis and Treatment (R01 - Clinical Trial Not Allowed) Apply for PAR 25 338 Funding Number: PAR 25 338 Agency: National Institutes of Health Category: Education, Health Funding Amount: $499,000 |
| Substance Use/Substance Use Disorder Dissertation Research Award (R36 Clinical Trials Not Allowed) Apply for PAR 25 347 Funding Number: PAR 25 347 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| Development of Medications to Prevent and Treat Substance Use Disorders and Overdose (UG3/UH3 - Clinical Trial Optional) Apply for PAR 25 329 Funding Number: PAR 25 329 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| Grand Opportunity in Medications Development for Substance-Use Disorders (U01 Clinical Trial Optional) Apply for PAR 25 328 Funding Number: PAR 25 328 Agency: National Institutes of Health Category: Education, Health Funding Amount: $5,000,000 |
| Method to Extend Research in Time (MERIT) Award Extension Request (Type 4 eSubmission Clinical Trial Optional) Apply for PAR 25 324 Funding Number: PAR 25 324 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| Unveiling Health and Healthcare Disparities in Non-Communicable and Chronic Diseases in Latin America: Setting the Stage for Better Health Outcomes Across the Hemisphere (R01 - Clinical Trials Not Allowed) Apply for PAR 25 377 Funding Number: PAR 25 377 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| Understanding the Intersection of Social Inequities to Optimize Health and Reduce Health Disparities: The Axes Initiative (R01 Clinical Trial Optional) Apply for RFA NR 25 004 Funding Number: RFA NR 25 004 Agency: National Institutes of Health Category: Education, Health Funding Amount: $500,000 |
| Multimodal Artificial Intelligence to Accelerate HIV Clinical Care (R01 Clinical Trial Optional) Apply for RFA MH 26 105 Funding Number: RFA MH 26 105 Agency: National Institutes of Health Category: Education, Health Funding Amount: $750,000 |
| Interventions on Health and Healthcare Disparities on Non-Communicable and Chronic Diseases in Latin America: Improving Health Outcomes Across the Hemisphere (R01 - Clinical Trial Required) Apply for PAR 25 342 Funding Number: PAR 25 342 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| NCI Pathway to Independence Award (K99/R00 Clinical Trial Required) Apply for PAR 25 313 Funding Number: PAR 25 313 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| Behavioral and Integrative Treatment Development Program (R34 Clinical Trial Optional) Apply for PAR 24 300 Funding Number: PAR 24 300 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| Development of Interventions to Prevent and Treat Substance Use Disorders and Overdose (UG3/UH3 - Clinical Trial Optional) Apply for PAR 25 446 Funding Number: PAR 25 446 Agency: National Institutes of Health Category: Education, Health Funding Amount: $3,000,000 |
| Community-Partnered Nursing Research Centers (P20 Clinical Trial Optional) Apply for PAR 25 439 Funding Number: PAR 25 439 Agency: National Institutes of Health Category: Education, Health Funding Amount: $500,000 |
| Dynamic and Adaptable Infrastructure for Drug Development and Outreach to Aid the Research Community in Advancing Medication Repurposing and Repositioning Efforts for Substance Use Disorders (SUDs) (U54 - Clinical Trials Not Allowed) Apply for RFA DA 26 020 Funding Number: RFA DA 26 020 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Inside Our Applicants Portal
Access Applicants Portal
- Grants Repository - Access current and historic funding opportunities with ease. Thousands of funding opportunities are published every week. We can help you sort through the database and find the eligible ones to apply for.
- Applicant Video Guides - The grant application process can be challenging to follow. We can help you with intuitive video guides to speed up the process and eliminate errors in submissions.
- Grant Proposal Wizard - We have developed a network of private funding organizations and investors across the United States. We can reach out and submit your proposal to these contacts to maximize your chances of getting the funding you need.
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Learn More
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "RFA CA 25 006", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.